About SCiStar Study
SCiStar is a clinical research study evaluating the safety and activity of AST-OPC1 oligodendrocyte progenitor cells, an investigational agent for newly injured people with sensorimotor cervical (in the neck) spinal cord injury. The SCiStar study will evaluate three increasing doses of AST-OPC1 administered at a single point in time between 21 and 42 days after injury. People who meet SCiStar study eligibility criteria will receive one of three AST-OPC1 doses as an injection in the spine.
AST-OPC1 consists of neural cells known as oligodendrocyte progenitor cells, which are produced from human embryonic stem cells. AST-OPC1 was previously tested in the world’s first human clinical trial of a stem cell derived product.
SCiStar study researchers are seeking adults between the ages of 18 and 69 who recently experienced a spinal cord injury in the neck that resulted in the loss of nearly all sensation and movement below the injury site, and some paralysis of both the arms and legs. Researchers will assess the impact of AST-OPC1 on hand and arm function as measured by the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI), the standard exam used to measure function in spinal cord injury patients.